Trial · NCT04414618
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Measurement of the Change in Oxygen Requirement From Baseline | Opaganib | -38.8 | 95% Confidence Interval -56.5 to 0 | L/min*day | |
| Measurement of the Change in Oxygen Requirement From Baseline | Placebo | -33.0 | 95% Confidence Interval -149.5 to -12.5 | L/min*day | |
| Measurement of Time to the Reduction in Oxygen Requirement. | Opaganib | 5.00 | 95% Confidence Interval 4.00 to 12.00 | Days | |
| Measurement of Time to the Reduction in Oxygen Requirement. | Placebo | 8.00 | 95% Confidence Interval 4.00 to NA | Days | |
| The Percentage of Subjects no Longer Receiving Supplemental Oxygen for at Least 24 Hours by Day 14 | Opaganib | 11 | Participants | ||
| The Percentage of Subjects no Longer Receiving Supplemental Oxygen for at Least 24 Hours by Day 14 | Placebo | 4 | Participants | ||
| Time to Negative Swabs for SARS-CoV-2 by PCR Post Treatment | Opaganib | NA | 95% Confidence Interval NA to NA | Days | |
| Time to Negative Swabs for SARS-CoV-2 by PCR Post Treatment | Placebo | NA | 95% Confidence Interval NA to NA | Days | |
| The Percentage of Subjects With at Least Two Consecutive Negative Swabs for SARS-CoV-2 by PCR at Day 14 | Opaganib | NA | Participants | ||
| The Percentage of Subjects With at Least Two Consecutive Negative Swabs for SARS-CoV-2 by PCR at Day 14 | Placebo | NA | Participants | ||
| Intubation and Mechanical Ventilation Requirements | Opaganib | 2 | Participants | ||
| Intubation and Mechanical Ventilation Requirements | Placebo | 2 | Participants | ||
| Evaluation of the Time to Intubation and Mechanical Ventilation | Opaganib | NA | 95% Confidence Interval NA to NA | Days | |
| Evaluation of the Time to Intubation and Mechanical Ventilation | Placebo | NA | 95% Confidence Interval NA to NA | Days | |
| Evaluation the Proportion of Patients, With at Least One Measurement of Fever at Baseline Who Are Afebrile at Day 14 | Opaganib | 3 | Participants | ||
| Evaluation the Proportion of Patients, With at Least One Measurement of Fever at Baseline Who Are Afebrile at Day 14 | Placebo | 0 | Participants | ||
| Evaluation of Mortality 30 Days Post-baseline | Opaganib | 3 | Participants | ||
| Evaluation of Mortality 30 Days Post-baseline | Placebo | 2 | Participants | ||
| Safety TEAEs | Opaganib | 11 | Participants | ||
| Safety TEAEs | Placebo | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04414618/results